跳至主要内容
临床试验/NCT01278693
NCT01278693已完成2 期

Study of Treatment of Dyslipidemia for Hemodialysis

Isfahan University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
54
试验地点
1
主要终点
lipid profile

研究概览

简要总结

The purpose of this study is to determine Effect of oral L-carnitine supplement on lipid profile, anemia, and quality of life.

详细描述

In patients under maintenance hemodialysis several factors reduce the body stored carnitine which in turn affected dyslipidemia, anemia, and general health in these patients. The investigators evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life in hemodialysis patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • being in the age range of 18-75 having the history of at least 12 weeks of hemodialysis and at least three times a week and each session almost for four hours having serum triglyceride or total cholesterol concentration >200 mg/dl or serum HDL concentration >40 mg/dl in the beginning of the study.

排除标准

  • taking carnitine supplement or the drug that interact with carnation lowering the seizure threshold in the last month being affected by liver function abnormalities, hypothyroidism, chronic infectious diseases (such as hepatitis), inflammatory diseases, CNS mass having the history of seizure.

研究组 & 干预措施

placebo

Other

it is as like as L-carnitine in shape

干预措施: placebo (Drug)

L-carnitine

Other

it is kind of supplement

干预措施: L-carnitine (Drug)

结局指标

主要结局

lipid profile

时间窗: at sixteen weeks after admission

次要结局

  • anemia(at sixteen weeks after admission)
  • quality of life(at sixteen weeks after admission)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验